share_log

Endexx Q3 Year-Over-Year Quarterly Sales Increase 246%

Endexx Q3 Year-Over-Year Quarterly Sales Increase 246%

Endexx第三季度銷售額同比增長246%
GlobeNewswire ·  2022/08/15 15:50

ENDEXX

尾數

Endexx Top Two Sellers in Pharmacies
Endexx在藥店的前兩名銷售商

Endexx Announces Fiscal Third Quarter 2022

Endexx宣佈2022財年第三季度

CAVE CREEK, AZ, Aug. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Endexx Corporation (OTC: EDXC), a provider of innovative plant based and sustainable health and skincare products now available in 8,000 Mass Retail and Pharmacy stores nationwide, today announced its Form 10Q, third quarter ending June 30, 2022.  Endexx continues to rebound and show growth in mass retail sales. The 8000 mass retail stores are in the early stages of growth and are anticipated to fluctuate and grow over the remainder of fiscal 2022 and accelerate in 2023 and 2024 respectively.  Endexx reported $418,151 in revenues in its third quarter of fiscal 2022 versus $120,801 in the third quarter of fiscal 2021, a 246% increase. Additionally, nine-month numbers showed an increase of 127% with $947,428 in the first 3 fiscal quarters of 2022 over $416,094 in the same period of fiscal 2021.­­­­­

亞利桑那州CaveCreek,2022年8月15日(Global Newswire)--Via NewMediaWire-Endexx Corporation(場外交易代碼:EDXC)是一家以植物為基礎的創新健康和護膚產品供應商,目前在全國8,000家大眾零售和藥店都有銷售,該公司今天宣佈了截至2022年6月30日的第三季度10Q報表。Endexx繼續反彈,大眾零售額出現增長。8000家大眾零售店正處於增長的早期階段,預計將在2022財年剩餘時間內波動和增長,並分別在2023年和2024年加速增長。Endexx報告其2022財年第三季度的收入為418,151美元,而2021財年第三季度的收入為120,801美元,增長了246%。此外,9個月的數據顯示,2022財年前3個季度的947,428美元比2021財年同期的416,094美元增長了127%。

"The third quarter showed continued expansion in revenues in Mass Retail stores. We currently are in the top two National Pharmacies and the largest premium Mass Retailer in the US," stated CEO Todd Davis. Davis added, "Opening orders in mass retail is the beginning of long-term sales cycles, expansion requires investment and Endexx has managed the challenges of this growth cycle as efficiently as possible given the current financial markets." Davis concluded, "With ongoing anticipation of Federal Regulatory advances, we believe this industry is still in its infancy and has the potential to become a leading multi-billion dollar growth industry in the next few years. According to Nielsen Ratings, Endexx's topical balm and topical cream are the Top Two selling CBD topical products in the pain aisle in Nationwide Pharmacies."

首席執行官託德·戴維斯表示:“第三季度大眾零售店的收入持續增長。我們目前躋身全國藥店前兩名,也是美國最大的高端大眾零售商。”Davis補充説:“大眾零售的開盤訂單是長期銷售週期的開始,擴張需要投資,鑑於目前的金融市場,Endexx已經儘可能有效地應對了這一增長週期的挑戰。”戴維斯總結説:“隨着對聯邦監管機構進步的持續預期,我們相信這個行業仍處於初級階段,有可能在未來幾年成為一個領先的數十億美元增長行業。根據尼爾森評級公司的數據,Endexx的外用藥膏和外用乳膏是全國藥店最暢銷的CBD外用產品。”

Recorded in Q3 financials is an extraordinary non-cash derivative liability.  This is due to the Double Diamond trading in April that allowed below market trading prices to be posted in time and sales records in quotation services. Endexx is working to correct the condition that created the non-cash derivative loss.

在第三季度財務報表中記錄了一項特殊的非現金衍生品負債。這是由於4月份的雙鑽石交易使低於市場交易價的交易得以及時公佈,並在報價服務中創造了銷售記錄。Endexx正在努力糾正造成非現金衍生品虧損的情況。

See 10Q filing at:

請參閲以下地址的10Q備案:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001109486/000149315222022763/form10-q.htm

Https://www.sec.gov/ix?doc=/Archives/edgar/data/0001109486/000149315222022763/form10-q.htm

Learn more about Endexx at:

有關Endexx的更多信息,請訪問:

&

&

To find Endexx products visit:

要查找Endexx產品,請訪問:

Visit and search for Blesswell or,

訪問和搜索布萊斯韋爾或,

Endexx highly recommends our customers and stakeholders to discover the value and experience our Blesswell™ Skincare products. Visit to learn more.

Endexx強烈建議我們的客户和利益相關者發現我們的價值並體驗我們的百威™護膚品。訪問以瞭解更多信息。

Try the top 2 selling products in the pain aisle

試試痛苦過道里最暢銷的兩款產品

Go to high performance Men's Grooming Products at:

請訪問高性能男士美容產品網站:

For a store located near you, visit websites below.

對於位於您附近的商店,請訪問下面的網站。

For more information about Endexx Corporation:

欲瞭解有關Endexx公司的更多信息,請訪問:

Visit:  , , , and

訪問:、、和

About Endexx Corporation

關於Endexx公司

Endexx Corporation, develops and distributes all-natural plant-derived topical skincare products. Its products vary from balms, creams, lotions, butters, masks, scrubs and oils all with the shared purpose of healthy skin and grooming wellness. The science behind these products involves a decade of clinical research in the field and lab work to provide functional formulation with ingredients for optimal absorption and the support of skin health.

Endexx公司,開發和分銷全天然植物衍生局部護膚品。它的產品種類繁多,從香膏、面霜、乳液、黃油、面膜、磨砂膏和油,所有這些都是為了健康皮膚和美容健康。這些產品背後的科學包括十年的現場臨牀研究和實驗室工作,以提供含有最佳吸收和支持皮膚健康的成分的功能配方。

Safe Harbor Notice

安全港通告

This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the company's business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update any forward-looking statements.

本新聞稿可能包含1995年私人證券訴訟改革法所指的“前瞻性陳述”,例如與財務結果和未來發展活動計劃有關的陳述,因此具有前瞻性。前瞻性陳述包括所有不是關於公司、其董事或高級管理人員的意圖、信念或當前期望的歷史事實的陳述。請投資者注意,任何此類前瞻性陳述都不是對未來業績的保證,涉及風險和不確定性,其中許多風險和不確定性超出了公司的控制能力。實際結果可能與前瞻性陳述中預測的結果大不相同。可能導致實際結果與前瞻性陳述中指出的大不相同的因素包括與公司總體業務和財務有關的風險和不確定因素,包括繼續和管理其增長、競爭、全球經濟狀況的能力,以及在公司提交給證券交易委員會的定期報告中詳細討論的其他因素。該公司沒有義務更新任何前瞻性陳述。

Contact:
For further investor and media information, contact:
Endexx Corporation
Todd Davis
Chairman & CEO
Endexx@endexx.com
480-595-6900

聯繫方式:
欲瞭解更多投資者和媒體信息,請聯繫:
Endexx公司
託德·戴維斯
董事長兼首席執行官
郵箱:endexx@endexx.com
480-595-6900

Attachment

依附

  • ENDEXX
  • 尾數

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論